Clinical Trials List
2025-01-15 - 2026-12-31
Phase III
Recruiting1
ICD-10N05.3
Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
ICD-10N05.4
Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
ICD-10N05.5
Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
ICD-10N06.3
Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis
ICD-10N06.4
Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis
ICD-10N06.5
Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis
ICD-10N07.3
Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis
ICD-10N07.4
Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis
ICD-10N07.5
Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis
ICD-9583.2
Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
2 participants
-
Global
106 participants
